No Data
Optimistic Buy Rating for Passage Bio as PBFT02 Shows Promising Results and Market Potential
Passage Bio Reveals Promising Gene Therapy Trial Results
Passage Bio to Present New Data on Gene Therapy for Frontotemporal Dementia at ISFTD2024
Press Release: Passage Bio Welcomes Tom Kassberg to Board of Directors
Passage Bio Appoints Thomas Kassberg to Leadership Team
Rodman & Renshaw Initiates Passage Bio(PASG.US) With Buy Rating, Announces Target Price $7
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Passage Bio(PASG.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate of 37.9